Stock Analysts’ updated eps estimates for Tuesday, November 14th:

AECOM (NYSE:ACM) had its hold rating reaffirmed by analysts at Canaccord Genuity. Canaccord Genuity currently has a $36.00 price target on the stock. The analysts wrote, “We reiterate a HOLD rating and lower our EBITDA and EPS estimates to reflect the mid- point of guidance. While the quarter was solid in terms of organic growth and overall backlog, growth for MS backlog, despite being up ~50%, is well below the 2x target referenced by management entering this year. On a positive note, the share buyback appears to be incremental to target model assumptions, which we expect management to revisit during its December 12 analyst day.””

Agree Realty Corporation (NYSE:ADC) was given a $58.00 target price by analysts at B. Riley. The firm currently has a buy rating on the stock.

Agnico Eagle Mines Limited (NYSE:AEM) (TSE:AEM) had its hold rating reissued by analysts at BMO Capital Markets. They currently have a $47.00 target price on the stock.

BeiGene (NASDAQ:BGNE) had its buy rating reaffirmed by analysts at Cowen and Company. The analysts wrote, “SGMO reported 3Q17 results and is on track to report first data from the Ph1/2 trials.””

Chesapeake Energy Corporation (NYSE:CHK) had its hold rating reaffirmed by analysts at BMO Capital Markets. BMO Capital Markets currently has a $4.00 price target on the stock.

Dova Pharmaceuticals (NASDAQ:DOVA) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Dova Pharmaceuticals, Inc. is a pharmaceutical company. It focuses on acquiring, developing and commercializing drug candidates for thrombocytopenia diseases. The company’s drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist which are in clinical stage. Dova Pharmaceuticals, Inc. is based in Durham, North Carolina. “

Diamondrock Hospitality (NYSE:DRH) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “DiamondRock Hospitality Company is a self-advised real estate company that owns, acquires and invests in upper upscale and upscale hotel properties located primarily in North America. To a lesser extent, it may invest, on a selective basis, in premium limited-service and extended-stay hotel properties in urban locations. The Company has a strategic acquisition sourcing relationship with Marriott International. “

Ellington Residential Mortgage REIT (NYSE:EARN) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Ellington Residential Mortgage REIT is a real estate investment trust that specializes in acquiring, investing in and managing residential mortgage and real estate-related assets. Ellington Residential Mortgage REIT is based in United States. “

Engility Holdings (NYSE:EGL) was upgraded by analysts at Noble Financial from a hold rating to a buy rating.

eMagin (NYSEAMERICAN:EMAN) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “eMagin Corporation is a leading developer of virtual imaging technology, eMagin combines integrated circuits, microdisplays, and optics to create a virtual image equivalent to the real image of a computer monitor or large screen TV. These miniature, high-performance, virtual imaging modules provide access to information-rich text, data, and video which can facilitate the opening of new mass markets for wearable PCs, wireless Internet appliances and mobile phones, portable DVD-viewers, digital cameras, and other emerging applications. “

Energizer Holdings (NYSE:EPC) was downgraded by analysts at Zacks Investment Research from a hold rating to a strong sell rating. According to Zacks, “Edgewell Personal Care Co. manufactures and markets personal care products. The company’s brand consists of Schick(R) and Wilkinson Sword(R) men’s and women’s shaving systems and disposable razors; Edge(R) and Skintimate(R) shave preparations; Playtex(R), Stayfree(R), Carefree(R) and o.b. (R) feminine care products; Banana Boat(R) and Hawaiian Tropic(R) sun care products; Playtex(R) infant feeding, Diaper Genie(R) and gloves; Wet Ones(R) moist wipes. Edgewell Personal Care Co., formerly known as Energizer Holdings, is based in St Louis, United States. “

Enterprise Products Partners L.P. (NYSE:EPD) had its buy rating reiterated by analysts at BMO Capital Markets. They currently have a $33.00 target price on the stock.

EQT Corporation (NYSE:EQT) had its buy rating reiterated by analysts at BMO Capital Markets. BMO Capital Markets currently has a $75.00 target price on the stock.

Envision Healthcare Corporation (NYSE:EVHC) had its hold rating reissued by analysts at Cantor Fitzgerald. Cantor Fitzgerald currently has a $30.00 target price on the stock. The analysts wrote, “Early today, Bloomberg reported that EVHC has attracted buyout interest from private equity firms, including Carlyle Group and Onex Corp., which may bid for EVHC alone or as part of a group. Shares rose as much as 14% during the day and closed up 10.3%.””

EXFO (NASDAQ:EXFO) (TSE:EXF) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “EXFO Inc. is a provider of next-generation test and service assurance solutions for wireless and wireline network operators and equipment manufacturers in the global telecommunications industry. The Company operates in two segments: Telecom Division, and the Life Sciences and Industrial Division. The Telecom Division offers a wide range of innovative solutions to assess optical networks, from the core to access, as well as next-generation IP infrastructures and related triple-play services. The Life Sciences and Industrial Division offers solutions in medical device and opto-electronics assembly, fluorescence microscopy and other life science sectors. EXFO Inc., formerly known as EXFO Electro-Optical Engineering Inc., is headquartered in Quebec, Canada. “

Diamondback Energy (NASDAQ:FANG) had its buy rating reissued by analysts at BMO Capital Markets. The firm currently has a $130.00 price target on the stock.

FARO Technologies (NASDAQ:FARO) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $58.00 target price on the stock. According to Zacks, “FARO Technologies, Inc. is the world’s most trusted source for 3D measurement technology. The Company develops and markets computer-aided measurement and imaging devices and software. Technology from FARO permits high-precision 3D measurement, imaging and comparison of parts and complex structures within production and quality assurance processes. The devices are used for inspecting components and assemblies, rapid prototyping, documenting large volume spaces or structures in 3D, surveying and construction, as well as for investigation and reconstruction of accident sites or crime scenes. FARO Technologies capture and analysis of on-site real world data to investigate crash, crime and fire, plan security activities and provide virtual reality training for public safety personnel, and also Capture detailed and precise 3D data from existing products permitting CAD analysis and redesign, after market design and legacy part replication. “

Hexcel Corporation (NYSE:HXL) had its hold rating reiterated by analysts at Canaccord Genuity. Canaccord Genuity currently has a $62.00 target price on the stock. The analysts wrote, “We spent a day on the road with Hexcel (HXL) management. The focus for HXL remains on the commercial OE cycle, and the cash conversion as build rates, notably on the new platforms (A350, 787, A320neo and 737 MAX) accelerate. HXL remains on track to hit its long-term FCF and revenue targets, and the recent move in the stock largely reflects the improved sentiment around the commercial cycle, bolstered by the 787- rate increase to 14/month, strong traffic, and renewed order activity, notably for Boeing. While HXL remains one of the best executing stocks in our universe, and we appreciate the straight-forward guidance and outlook, we are looking potential catalysts that can provide additional upside or improved sentiment. We are maintaining our HOLD rating and our $62 price target.””

Irhythm Tech (NASDAQ:IRTC) had its buy rating reiterated by analysts at Canaccord Genuity. They currently have a $59.00 price target on the stock. The analysts wrote, “We expect these data, assuming the read-out of the full study data follows suit (which we expect), will build IRTC’s case with payers, paving the way ultimately for prospective screening with Zio in a brand new, 3- million-patient TAM. While not in our model at all, we think over time, payors will cover Zio for screening of high-risk patients defined by the mSToPs study. We reiterate our BUY rating and $59 price target.””

Jagged Peak Energy (NYSE:JAG) had its buy rating reaffirmed by analysts at BMO Capital Markets. They currently have a $17.00 price target on the stock.

Swift Transportation (NYSE:KNX) was upgraded by analysts at Knight Equity to a buy rating.

LivaNova PLC (NASDAQ:LIVN) had its hold rating reissued by analysts at Canaccord Genuity. The firm currently has a $76.00 target price on the stock. The analysts wrote, “We stay HOLD rated on LIVN coming out of constructive meetings with management on the road last week. We continue to believe the firm possesses intriguing long-term growth initiatives –in transcatheter mitral valve replacement (TMVR), heart failure (HF) and treatment-resistant depression (TRD) – but anticipate these segments will take several years to materialize and likely require additional M&A and material R&D spending before either the TMVR or HF initiatives could potentially contribute to LIVN’s top- and bottom-line growth profiles. That said, we sensed incrementally stronger conviction from management regarding both robust GM expansion potential as well as low-DD revenue growth from the emerging markets (ROW) business. Taken together, we management seems confident it can deliver merger integration cost synergies that the think these drivers could help the firm hit or exceed its guidance in 4Q:17.””

Remark Media (NASDAQ:MARK) had its target price raised by Roth Capital to $8.00. Roth Capital currently has a buy rating on the stock.

Myovant Sciences (NASDAQ:MYOV) had its buy rating reissued by analysts at Cowen and Company. The analysts wrote, “Myovant reported a FQ2:18 net loss of $29.9MM and a 9/30 cash balance of.””

Puma Biotechnology (NASDAQ:PBYI) was downgraded by analysts at BidaskClub from a strong-buy rating to a buy rating.

PDC Energy (NASDAQ:PDCE) had its hold rating reaffirmed by analysts at BMO Capital Markets. BMO Capital Markets currently has a $55.00 target price on the stock.

Reata Pharmaceuticals (NASDAQ:RETA) had its buy rating reissued by analysts at Cowen and Company. The analysts wrote, “RETA reported 3Q17 financials yesterday, noting that the three major programs.””

Regulus Therapeutics (NASDAQ:RGLS) had its hold rating reissued by analysts at Needham & Company LLC. The analysts wrote, “Regulus reported 3Q17 financial results last wk and we met w/ mgmt for an update today. Both planned clinical trials of RG-012 in Alport Syndrome pts are now underway and an IND has been submitted for RGLS4326 in Autosomal Dominant Polycystic Kidney Disease. Mgmt has identified male X-linked Alport Syndrome as target pt population for clinical development going forward, due to rapid and homogeneous disease progression. We expect top-line results from 10- patient RG-012 biopsy trial early next yr and from 40-patient RG-012 HERA Phase 2 efficacy trial in early 2019. Maintain HOLD, awaiting more data from lead RG-012 program, but also note encouraging progression of platform/ pipeline behind it.””

Range Resources Corporation (NYSE:RRC) had its buy rating reiterated by analysts at BMO Capital Markets. The firm currently has a $30.00 price target on the stock.

Rhythm Pharmaceuticals (NASDAQ:RYTM) had its buy rating reissued by analysts at Needham & Company LLC. Needham & Company LLC currently has a $32.00 price target on the stock. The analysts wrote, “Rhythm reported 3Q17 financial results and we spoke w/ mgmt for an update. Enrollment in Phase 3 setmelanotide trial in POMC Deficiency is still expected to be completed by YE17. We assume top-line results in early 2019 (unch) and continue to expect a positive outcome. Mgmt also reiterated guidance for intiation of Phase 3 setmelanotide trial in LepR Deficiency by YE17. Data in a small number of patients with POMC or LepR Deficiency were remarkably strong and are the basis for our enthusiasm for the drug and the stock. We await data from Phase 2 trials in Alstrom Syndrome and POMC Epigenetic/ Heterozygous mutation patients in early 2018. A favorable outcome would add meaningfully to peak sales potential. BUY.””

Rhythm Pharmaceuticals (NASDAQ:RYTM) had its buy rating reissued by analysts at Cowen and Company. The firm currently has a $40.00 price target on the stock. The analysts wrote, “Rhythm released Q3 financials this morning, following the presentation of promising.””

SRC Energy (NYSEAMERICAN:SRCI) had its hold rating reissued by analysts at BMO Capital Markets. BMO Capital Markets currently has a $10.00 target price on the stock.

TJX Companies, Inc. (The) (NYSE:TJX) was given a $76.00 target price by analysts at Wells Fargo & Company. The firm currently has a buy rating on the stock.

Weibo (NASDAQ:WB) had its price target increased by Barclays PLC. The firm currently has an overweight rating on the stock.

Wildhorse Resource Development Corporation (NYSE:WRD) had its buy rating reiterated by analysts at BMO Capital Markets. BMO Capital Markets currently has a $21.00 target price on the stock.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) had its target price boosted by Piper Jaffray Companies from $16.00 to $20.00.

Receive News & Ratings for AECOM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AECOM and related companies with Analyst Ratings Network's FREE daily email newsletter.